

# Have there been any positive innovations within cancer services as a result of COVID-19?



**Sample:** 60 oncologists

**Methodology:** Online survey

**Screening:** All involved in the treatment and management of one or more of the following tumour types: *Colorectal, Breast, Lung, Prostate, Pancreatic, Stomach, Liver*

**Scope:** EU5 (*UK, France, Germany, Italy, Spain*)

44% of oncologists cited virtual consultations as a positive change made during COVID-19

## Positive changes to services during COVID-19

Virtual MDTs IT improvements

Home based care


# Virtual consultations

None Virtual tumour conferences



Q3a

Majority of oncologists are open to further innovation of cancer services




Q3

## Most oncologists believe that some services set-up during the COVID-19 pandemic should become a more permanent part of the cancer care pathway

■ % of oncologists working in cancer centres where new services were set up during COVID-19

■ % of oncologists that perceive new services should be permanently included in cancer care pathways



S4 Q4

Q3a What, if any, positive changes have there been to cancer services as a result of COVID-19. Q3. How receptive are you to further innovation within the cancer care pathway e.g. to the cancer services your center provides? On a scale of 1 to 7, where 1= not at all receptive to further innovation and 7 = extremely receptive to further innovation. S4. Which of the following changes / innovations have been introduced in your cancer center during the COVID-19 pandemic? Q4. Which, if any, of the cancer services set-up during the COVID-19 pandemic do you think should become a more permanent part of the cancer care pathway? Select all that apply

Contact [claire.jackson@7i-group.com](mailto:claire.jackson@7i-group.com) or [www.7i-group.com](http://www.7i-group.com) to receive the full article



# Can the pharmaceutical industry support healthcare systems with service and cancer pathway changes?

Sample: 60 oncologists that treat and manage patients with one of more of following tumour types: *colorectal, lung, liver, breast, stomach, pancreatic, prostate*

Methodology: Online survey

Scope: EU5 (*UK, France, Germany, Italy, Spain*)



68% of oncologists

cited that the pharmaceutical industry could support either the development, implementation or optimization of new cancer care services



22%

Home treatment and monitoring-  
patient & nurse education &  
pathway creation



15%

Funding



8%

Development of new technologies  
e.g. patient apps



7%

Assisting with remote  
consultations



5%

Digital communications  
with pharma

Q5: Do you feel that the pharmaceutical industry could, in some way, support the development, implementation or optimisation of new cancer care services? In what way?

Contact [claire.jackson@7i-group.com](mailto:claire.jackson@7i-group.com) or [www.7i-group.com](http://www.7i-group.com) to receive the full article